Company: LIMN
Filing Date: 2025-06-24
Form Type: S-1
Source: 0001410578-25-001432
Chunk: 104

Company: Liminatus Pharma, Inc.
Filing Date: 2025-06-24
Form: S-1
Chunk 104
---
| ● | conduct clinical trials for our CD47 product, as well as initiate and complete additional trials of future potential product candidates; |

| ● | seek regulatory approval for any product candidates that successfully complete clinical trials; |

| ● | scale up our clinical and regulatory capabilities; |

| ● | manufacture materials for clinical trials or potential commercial sales; |

| ● | establish a commercialization infrastructure and scale up manufacturing and distribution capabilities to commercialize any product candidates for which we may obtain regulatory approval; |

| ● | adapt our regulatory compliance efforts to incorporate requirements applicable to marketed products; |

| ● | maintain, expand, and protect our intellectual property portfolio; |

66

| ● | hire additional clinical, manufacturing quality control, regulatory, manufacturing, and scientific and administrative personnel; |

| ● | add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts; and |

| ● | incur additional legal, accounting, and other expenses in operating as a public company. |

Business Combination On November 30, 2022, Iris Acquisition Corporation, a Delaware corporation (“Iris”), Iris Parent Holding Corp. (“ParentCo”), Liminatus Pharma, LLC, Liminatus Pharma Merger Sub, Inc. (“Liminatus Merger Sub”) and SPAC Merger Sub, Inc. (“SPAC Merger Sub”) entered into a business combination agreement (as it may be amended, supplemented or otherwise modified from time to time, the “Business Combination Agreement”). On April 30, 2025, ParentCo consummated the business combination contemplated by the Business Combination Agreement, whereby (a) Liminatus Merger Sub merged with and into Liminatus (the “Liminatus Merger”), with Liminatus Pharma, LLC surviving the Liminatus Merger as a direct wholly-owned subsidiary of ParentCo, and (b) simultaneously with the Liminatus Merger, SPAC Merger Sub merged with and into Iris (the “SPAC Merger” and, together with the Liminatus Merger, the “Mergers”), with Iris surviving the SPAC Merger as a direct wholly-owned subsidiary of ParentCo (the transactions contemplated by the foregoing clauses (a) and (b) the “Business Combination”). Upon the closing of the Business Combination, the combined company was named “Liminatus Pharma, Inc.” Pursuant to the Business Combination Agreement, among other matters, at the effective time of the Business Combination (the “Effective Time”),